Virologic outcomes of changing enfuvirtide to raltegravir in HIV-1 patients well controlled on an enfuvirtide based regimen: 24-Week results of the CHEER study

Journal of Acquired Immune Deficiency Syndromes

Volumn 51, Issue 4, 2009, Pages 367-373

  Towner, William ^a,f   Klein, Daniel ^b   Kerrigan, Hai Linh ^a   Follansbee, Stephen ^c   Yu, Kalvin ^d   Horberg, Michael ^e  

^a Kaiser Permanente ^*  (United States)

^b Division of Infectious Diseases   (United States)

^c Division of Infectious Diseases   (United States)

^d Division of Infectious Diseases   (United States)

^e DIVISION OF RESEARCH   (United States)

^f KAISER PERMANENTE   (United States)

Author keywords

Combination antiretroviral theapy; Enfuvirtide; HIV AIDS; Raltegravir

Indexed keywords

AMIKACIN; CLARITHROMYCIN; ENFUVIRTIDE; ETHAMBUTOL; MOXIFLOXACIN; PROTEINASE INHIBITOR; RALTEGRAVIR; RIFABUTIN; RITONAVIR; RITONAVIR PLUS TIPRANAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; AGED; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC KETOACIDOSIS; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; GASTROENTERITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT SATISFACTION; PRIORITY JOURNAL; SEPTICEMIA; SIDE EFFECT; VIREMIA; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AGED; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PROSPECTIVE STUDIES; PYRROLIDINONES; RNA, VIRAL; TREATMENT OUTCOME;

EID: 68049148420     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181ae35de     Document Type: Article

References (15)

1. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Department of Health and Human Services. January 29, 2008; 1-128. Available at: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed June 5, 2008.
2. Lalezari J, Henry K, O'Hearn M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2186-2195. (Pubitemid 36618128)
3. Lazzarin A, Clotet B, Cooper D, et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2175-2185. Epub Mar 13, 2003. Erratum in: N Engl J Med. 2003;349:1100.
4. Nelson M, Arasteh K, Clotet B, et al. Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials. J Acquir Immune Defic Syndr. 2005;40:404-412. (Pubitemid 41669173)
5. Grinsztein B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261-1269. (Pubitemid 46553846)
6. Steigbigel R, Cooper D, Kumar P, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359:339-354.
7. Hazuda D, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science. 2000;287:646-650. (Pubitemid 30070911)
8. Johnson V, Brun-Vézinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1: Spring 2008. Top HIV Med. 2008;16:62-68.
9. Khanlou H, Allavena C, Billaud E, et al. Development of hepatic cytolysis after switching from enfuvirtide to raltegravir in virologically suppressed patients treated with tipranavir/ritonavir (TUPE0087). Presented at: XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.
10. Harris M, Larsen G, Montaner J. Outcomes of multidrug-resistant patients switched from enfuvirtide to raltegravir within a virologically suppressive regimen. AIDS. 2008;22:1224-1226.
11. Teague A, Scott C, Youngstein T, et al. Clinical experience with raltegravir (MK-0518 or Isentress®), with an optimized background regimen in highly treatment-experienced patients (TUPE0106). Presented at: XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.
12. Talbot A, Machouf N, Thomas T, et al. Retrospective analysis of a switch from enfuvirtide to raltegravir in patients with undetectable viral load: efficacy and safety at 12 weeks in a Montreal cohort (TUPE0112). Presented at: XVII International AIDS Conference; August 3-8, 2008; Mexico City, Mexico.
13. Cohen C, Dusek A, Green J, et al. Long-term treatment with subcutaneous T-20, a fusion inhibitor, in HIV-infected patients: patient satisfaction and impact on activities of daily living. AIDS Patient Care STDS. 2002;16:327-335. (Pubitemid 34755961)
14. Cohen C, Clumeck N, Molina J, et al. Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen. J Acquir Immune Defic Syndr. 2004;37:1140-1146. (Pubitemid 39166648)
15. Eron J, Andrade J, Zajdenverg R, et al. Switching from stable lopinavir/ ritonavir-based to raltegravir-based combination ART resulted in a superior lipid profile at week 12 but did not demonstrate non-inferior virologic efficacy at week 24 (70aLB). Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada.